Serial #79392836
LIVE

Serial Number

79392836

Owner

Wuxi Biologics (Shanghai) Co., Ltd.

Attorney

Michael T. Smith

Filing Date

Nov 28, 2023

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79392836 Trademark

Serial Number: 79392836 • Registration: 7830513

Serial #79392836 is a trademark filed by Wuxi Biologics (Shanghai) Co., Ltd. on November 28, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Wuxi Biologics (Shanghai) Co., Ltd. (11 trademarks)

Building 2, No. 31 Yiwei Road,

Entity Type: 03

Trademark Details

Filing Date

November 28, 2023

Registration Date

June 17, 2025

Published for Opposition

April 29, 2025

Goods & Services

Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; providing medical information; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistance

Chemical-pharmaceutical preparations for the treatment of blood cancer, solid tumor, cancer or tumor, autoimmune disease, non-communicable diseases, Neurodegenerative diseases, aging-related diseases, coagulation disorder and infectious disease; biochemical medicines for the treatment of blood cancer, solid tumor, cancer or tumor, autoimmune disease, non-communicable diseases, Neurodegenerative diseases, aging-related diseases, coagulation disorder and infectious disease; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes for the treatment of blood cancer, solid tumor, cancer or tumor, autoimmune disease, non-communicable diseases, Neurodegenerative diseases, aging-related diseases, coagulation disorder and infectious disease; drugs for medical purposes, namely medicines for the treatment of blood cancer, solid tumor, cancer or tumor, autoimmune disease, non-communicable diseases, Neurodegenerative diseases, aging-related diseases, coagulation disorder and infectious disease; pharmaceutical preparations for the treatment of blood cancer, solid tumor, cancer or tumor, autoimmune disease, non-communicable diseases, Neurodegenerative diseases, aging-related diseases, coagulation disorder and infectious disease; drugs for treatment of cancer; medical preparation for treating diseases and disorders related to the immune system; biological agent, namely biologic preparations for treating cancer; pharmaceutical preparations for the prevention and treatment of cancer; living cells for medical use; oncolytic viral therapies; medical cell inhibitor, namely protein, antibody and small molecule inhibitor; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; pharmaceutical preparations, namely tumor suppressor; cells for medical use; dietetic food and substances adapted for medical use; biological preparations for veterinary purposes for the treatment of blood cancer, solid tumor, cancer or tumor, autoimmune disease, non-communicable diseases, Neurodegenerative diseases, aging-related diseases, coagulation disorder and infectious disease

Research and development of new products for others; technological research in the field of pharmaceutical studies, cell separation and cell culture; chemical analysis; biochemistry research and analysis; research and development in the field of pharmaceutical preparations; medical research service; research and development services in the field of antibodies; stem cell research services; medical research; medical and scientific research, namely conducting clinical trials for others; biological research; computer programming in the field of medical aspects

Online advertising on a computer network; advertising services; publicity agents; dissemination of advertising and advertising matter in the nature of flyers, prospectuses, brochures, leaflets and samples; providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing; sponsorship search; retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 29, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 14, 2026 FICS
FINAL DISPOSITION PROCESSED
Jan 14, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 19, 2025 OPNX
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 17, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 3, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 17, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 17, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 29, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 29, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 23, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 21, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 21, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 13, 2025 GNFN
FINAL REFUSAL E-MAILED
Jan 13, 2025 GNFR
FINAL REFUSAL WRITTEN
Jan 13, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 10, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 10, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 11, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 22, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 22, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 27, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 26, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 26, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 9, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 5, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 4, 2024 REPR